ANAPTYSBIO, INC(ANAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,408 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ANAB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ANAPTYSBIO, INC (ANAB), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ANAB at 29.4/100 on a 32-signal composite quality model, placing it at rank #2,408 of 2,879 stocks — the bottom half of the AI-ranked universe. ANAB scores in the top quartile across revenue growth (98.3). Areas of concern include balance sheet strength (7.0) and free cash flow (7.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 12.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ANAPTYSBIO, INC reports quarterly revenue of $25.6M, net income of $-52.9M, free cash flow of $-25.9M. Top institutional holders of ANAB by reported 13-F value include EcoR1 Capital,, BlackRock,, TANG CAPITAL MANAGEMENT, based on the most recent SEC filings. ANAB trades on the Nasdaq exchange and files with the SEC under CIK 1370053. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ANAPTYSBIO, INC directly from SEC EDGAR.
Revenue
Q1 2026
$25.6M
Net Income
Q1 2026
$-52.9M
Free Cash Flow
Q1 2026
$-25.9M
Get alerted when ANAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ANAPTYSBIO, INC including:
Top Institutional Holders of ANAB
EcoR1 Capital, LLC
$437.0M7,880,094 shBlackRock, Inc.
$93.2M1,681,380 shTANG CAPITAL MANAGEMENT LLC
$73.8M1,330,879 shMORGAN STANLEY
$55.1M993,905 shSTATE STREET CORP
$55.0M992,445 shAffinity Asset Advisors, LLC
$52.1M940,000 shVANGUARD CAPITAL MANAGEMENT LLC
$47.3M853,151 shPalo Alto Investors LP
$35.4M638,161 sh683 Capital Management, LLC
$34.7M625,000 shD. E. Shaw & Co., Inc.
$32.1M579,296 sh
| Fund | Value | Shares |
|---|---|---|
| EcoR1 Capital, LLC | $437.0M | 7,880,094 |
| BlackRock, Inc. | $93.2M | 1,681,380 |
| TANG CAPITAL MANAGEMENT LLC | $73.8M | 1,330,879 |
| MORGAN STANLEY | $55.1M | 993,905 |
| STATE STREET CORP | $55.0M | 992,445 |
| Affinity Asset Advisors, LLC | $52.1M | 940,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $47.3M | 853,151 |
| Palo Alto Investors LP | $35.4M | 638,161 |
| 683 Capital Management, LLC | $34.7M | 625,000 |
| D. E. Shaw & Co., Inc. | $32.1M | 579,296 |
More Healthcare Companies
View all Healthcare →Put ANAB on your watchlist
Track score changes the day ANAPTYSBIO, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANAB a good stock to buy?
13F Pro's AI-powered analysis of ANAPTYSBIO, INC (ANAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANAB are available on the ANAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ANAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ANAPTYSBIO, INC's investment landscape.